<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_abm-2018-0026_s_005_w2aab3b7b1b1b6b1aab1c17b1Aa"><h3>Background</h3><p>Non-alcoholic fatty liver disease (NAFLD) is one of the major causes of chronic liver disease. The primary treatment of NAFLD by statins has not been clearly elucidated.</p></sec><sec id="j_abm-2018-0026_s_006_w2aab3b7b1b1b6b1aab1c17b2Aa"><h3>Objectives</h3><p>To evaluate the effectiveness of statin use in patients with biopsy-proven NAFLD or non-alcoholic steatohepatitis on the change in liver histology.</p></sec><sec id="j_abm-2018-0026_s_007_w2aab3b7b1b1b6b1aab1c17b3Aa"><h3>Methods</h3><p>We searched MEDLINE, Scopus, Google Scholar, and the Cochrane Central Register of Controlled Trials for clinical trials and observational studies investigating the effects of statins on histological change regardless of type or dosage from inception to December 2015. Random-effect model meta-analyses were used to compute changes in outcomes of interest. The study protocol was registered in advance with the International Prospective Register of Systematic Reviews (PROSPERO 2016 CRD42016033132).</p></sec><sec id="j_abm-2018-0026_s_008_w2aab3b7b1b1b6b1aab1c17b4Aa"><h3>Results</h3><p>We identified 6 studies (111 patients), representing 5 cohort studies and 1 randomized controlled clinical trial. There was significant decrease in steatosis grading with a standardized mean difference of –2.580 (95% confidence interval [CI] –4.623 to –0.536; <italic>P</italic> = 0.013) and NAFLD activity score standardized mean difference of –1.488 (95% CI –2.506 to –0.471; <italic>P</italic> = 0.004). However, there was no significant change in fibrosis stage (0.156; 95% CI –0.553 to 0.865; <italic>P</italic> = 0.667).</p></sec><sec id="j_abm-2018-0026_s_009_w2aab3b7b1b1b6b1aab1c17b5Aa"><h3>Conclusions</h3><p>Statin use can possibly reduce the extent of steatohepatitis but not the stage of fibrosis. Further randomized controlled studies to assess histological evidence with adequate sample size and duration are required in order to establish the role of statin as a primary treatment of NAFLD.</p></sec></abstract>

BackgroundNon-alcoholic fatty liver disease (NAFLD) is one of the major causes of chronic liver disease. The primary treatment of NAFLD by statins has not been clearly elucidated.ObjectivesTo evaluate the effectiveness of statin use in patients with biopsy-proven NAFLD or non-alcoholic steatohepatitis on the change in liver histology.MethodsWe searched MEDLINE, Scopus, Google Scholar, and the Cochrane Central Register of Controlled Trials for clinical trials and observational studies investigating the effects of statins on histological change regardless of type or dosage from inception to December 2015. Random-effect model meta-analyses were used to compute changes in outcomes of interest. The study protocol was registered in advance with the International Prospective Register of Systematic Reviews (PROSPERO 2016 CRD42016033132).ResultsWe identified 6 studies (111 patients), representing 5 cohort studies and 1 randomized controlled clinical trial. There was significant decrease in steatosis grading with a standardized mean difference of –2.580 (95% confidence interval [CI] –4.623 to –0.536; P = 0.013) and NAFLD activity score standardized mean difference of –1.488 (95% CI –2.506 to –0.471; P = 0.004). However, there was no significant change in fibrosis stage (0.156; 95% CI –0.553 to 0.865; P = 0.667).ConclusionsStatin use can possibly reduce the extent of steatohepatitis but not the stage of fibrosis. Further randomized controlled studies to assess histological evidence with adequate sample size and duration are required in order to establish the role of statin as a primary treatment of NAFLD.

Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis

Department of Medicine, Division of Gastroenterology, Faculty of Medicine

Department of Medicine, Division of Nephrology, Faculty of Medicine

Center of Excellence in Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

BackgroundNon-alcoholic fatty liver disease (NAFLD) is one of the major causes of chronic liver disease. The primary treatment of NAFLD by statins has not been...

Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis

Article Category: Review article

Publié en ligne: 31 déc. 2018

Pages: 3 - 13

DOI: https://doi.org/10.1515/abm-2018-0026

Mots clés
fatty liver, fatty liver disease, HMG-CoA, hydroxymethylglutaryl-CoA reductase inhibitors, non-alcoholic, statins, steatohepatitis

© 2018 Pakkapon Rattanachaisit et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis

Article Category: Review article

Publié en ligne: 31 déc. 2018

Pages: 3 - 13

DOI: https://doi.org/10.1515/abm-2018-0026

Mots clésfatty liver, fatty liver disease, HMG-CoA, hydroxymethylglutaryl-CoA reductase inhibitors, non-alcoholic, statins, steatohepatitis

© 2018 Pakkapon Rattanachaisit et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
fatty liver, fatty liver disease, HMG-CoA, hydroxymethylglutaryl-CoA reductase inhibitors, non-alcoholic, statins, steatohepatitis